Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / VTA1



This biomarker is also known as:
  • SBP1,
  • LYST-interacting protein 5,
  • DRG1,
  • dopamine-responsive gene 1 protein,
  • Q9NP79,
  • SKD1-binding protein 1,
  • chromosome 6 open reading frame 55,
  • DRG-1,
  • Vps20-associated 1 homolog (S. cerevisiae),
  • vacuolar protein sorting-associated protein VTA1 homolog,
  • C6orf55,
  • My012,
  • Dopamine-responsive gene 1 protein,
  • LIP5,
  • HSPC228,
  • homolog of mouse SKD1-binding protein 1,
  • C6ORF55,

View in BioMuta


VTA1 (C6ORF55) is involved in activities of the multivesicular body, an endosomal compartment involved in sorting membrane proteins for degradation in lysosomes. VTA1 is thought to be a cofactor of VPS4A/B. VTA1 is involved in HIV-1 budding. It has been shown by similarity to be involved in the sorting and down-regulation of EGFR.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


No additional ovarian data available.

Performance Comment

VTA1 (C6ORF55) was one of 50 tumor vasculature-associated genes with transmembrane or secreted protein products identified through expression profiling of ovarian cancer vascular cells. These 50 tumor vascular markers (TVMs) also had low or no expression in normal tissues. VTA1 (C6ORF55) was not in the group of 13 selected for further validation.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.